1. Home
  2. EVH vs MLYS Comparison

EVH vs MLYS Comparison

Compare EVH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVH
  • MLYS
  • Stock Information
  • Founded
  • EVH 2011
  • MLYS 2019
  • Country
  • EVH United States
  • MLYS United States
  • Employees
  • EVH N/A
  • MLYS N/A
  • Industry
  • EVH Other Consumer Services
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVH Consumer Discretionary
  • MLYS Health Care
  • Exchange
  • EVH Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • EVH 1.2B
  • MLYS 1.0B
  • IPO Year
  • EVH 2015
  • MLYS 2023
  • Fundamental
  • Price
  • EVH $11.38
  • MLYS $15.02
  • Analyst Decision
  • EVH Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • EVH 14
  • MLYS 4
  • Target Price
  • EVH $16.79
  • MLYS $27.00
  • AVG Volume (30 Days)
  • EVH 3.3M
  • MLYS 892.7K
  • Earning Date
  • EVH 08-07-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • EVH N/A
  • MLYS N/A
  • EPS Growth
  • EVH N/A
  • MLYS N/A
  • EPS
  • EVH N/A
  • MLYS N/A
  • Revenue
  • EVH $2,398,737,000.00
  • MLYS N/A
  • Revenue This Year
  • EVH N/A
  • MLYS N/A
  • Revenue Next Year
  • EVH $16.14
  • MLYS N/A
  • P/E Ratio
  • EVH N/A
  • MLYS N/A
  • Revenue Growth
  • EVH 10.24
  • MLYS N/A
  • 52 Week Low
  • EVH $7.06
  • MLYS $8.24
  • 52 Week High
  • EVH $33.63
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • EVH 65.62
  • MLYS 55.98
  • Support Level
  • EVH $10.86
  • MLYS $13.44
  • Resistance Level
  • EVH $12.07
  • MLYS $14.70
  • Average True Range (ATR)
  • EVH 0.49
  • MLYS 0.70
  • MACD
  • EVH -0.01
  • MLYS 0.14
  • Stochastic Oscillator
  • EVH 62.47
  • MLYS 92.31

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: